This article examines the legal feasibility of establishing binding performance obligations on multinational corporations to mitigate their human rights violations given their status as superpowers. A bibliographic methodology was employed for this purpose. It was found that the predominant factors are related to the exacerbated desire for profitability, manifested within the framework of economic freedoms, as well as the dynamics of the international legal system itself. The case of pharmaceutical companies, whose natural market constitutes the very object of the right to health, was taken into account for this analysis.